Heart MRI with manganese dye could reveal hidden clues in common heart failure

NCT ID NCT06652763

Recruiting now Knowledge-focused Sponsor: University of Leicester Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses advanced MRI scans with a special manganese dye to look at how the heart handles calcium and energy in people with heart failure with preserved ejection fraction (HFpEF). Researchers will compare 40 people with HFpEF (half with type 2 diabetes) and 20 healthy volunteers. The goal is to understand why diabetes makes HFpEF worse, which could lead to better treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: manganese contrast dye
What this could lead to: If successful, this could reveal why heart failure with preserved ejection fraction is worse in people with type 2 diabetes, pointing toward new treatment targets.
What could go wrong: This is a small, early observational study (60 participants) that aims to understand the disease, not test a treatment. It may not lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION TYPE 2 DIABETES

Contacts and locations

Locations

University of Leicester
RECRUITING

Leicester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.